Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
93 hedge funds and large institutions have $80M invested in Evofem Biosciences, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 25 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 20
31% more call options, than puts
Call options by funds: $2.16M | Put options by funds: $1.65M
6% less funds holding
Funds holding: 99 → 93 (-6)
7% less capital invested
Capital invested by funds: $86.3M → $80M (-$6.36M)
20% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$676K |
| 2 |
BlackRock
New York
|
+$626K |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$608K |
| 4 |
State Street
Boston,
Massachusetts
|
+$493K |
| 5 |
D.E. Shaw & Co
New York
|
+$469K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$2.91M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$2.83M |
| 3 |
HP
Hound Partners
New York
|
-$2.44M |
| 4 |
Morgan Stanley
New York
|
-$1.62M |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$867K |
EVFM Hedge Fund Activity: Q4 2020 in Review
93 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2020, worth a combined $80M — down 7.4% from $86.3M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of EVFM and 20 opened new positions — a net loss of 5 holders — while 20 trimmed existing stakes and 29 added.
The largest buyer was Millennium Management, adding an estimated $676K. The largest seller was Jupiter Asset Management, exiting entirely with an estimated $2.91M sold.
- 93 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2020, down from 99 in Q3 2020.
- Funds reported $80M of Evofem Biosciences, Inc. Common Stock stock for Q4 2020, down 7.4% quarter-over-quarter.
- 20 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2020 and 25 closed out, a net change of -5 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q4 2020 was Millennium Management, an estimated $676K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q4 2020 was Jupiter Asset Management, an estimated $2.91M sold.
Based on aggregated 13F filings for Q4 2020.